Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Fgl2 As A Predictive Biomarker For Prognosis And Immunotherapy In Bladder Cancer.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Fgl2 As A Predictive Biomarker For Prognosis And Immunotherapy In Bladder Cancer.

    • Related Experiment Video

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.3K

    FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.

    Zhengnan Huang1, Zeyi Wang2, Chengdang Xu1

    • 1Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.

    International Journal of Medical Sciences
    |June 21, 2024

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Fibrinogen-like 2 (FGL2) is downregulated in bladder cancer (BLCA) due to promoter hypermethylation, correlating with poor prognosis. High FGL2 expression predicts better response to immunotherapy in BLCA patients.

    Keywords:
    FGL2bladder cancerimmunotherapyprognosistumor microenvironment.

    More Related Videos

    Predictive Immune Modeling of Solid Tumors
    08:50

    Predictive Immune Modeling of Solid Tumors

    Published on: February 25, 2020

    6.9K
    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    14.7K

    Related Experiment Videos

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.3K
    Predictive Immune Modeling of Solid Tumors
    08:50

    Predictive Immune Modeling of Solid Tumors

    Published on: February 25, 2020

    6.9K
    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    14.7K

    Area of Science:

    • Oncology
    • Immunology
    • Molecular Biology

    Background:

    • Metastasis and immunosuppression are key factors in the poor prognosis of bladder cancer (BLCA).
    • The roles of fibrinogen-like protein 1 (FGL1) and fibrinogen-like protein 2 (FGL2) in BLCA remain largely unexplored.

    Purpose of the Study:

    • To investigate the expression profile and prognostic significance of FGL1 and FGL2 in BLCA.
    • To explore the correlation between FGL2 expression and the tumor microenvironment, including immune cell infiltration and response to immunotherapy.

    Main Methods:

    • Analysis of FGL1 and FGL2 expression in BLCA using multiple databases and validation in patient tissues.
    • Prognostic evaluation of FGL2 using Kaplan-Meier analysis, univariate and multivariate Cox regression, and nomogram construction.
    • Functional enrichment analyses (GO, KEGG, GSEA) and assessment of FGL2's correlation with immune characteristics and immunotherapy response.

    Main Results:

    • FGL2 was found to be downregulated in BLCA, associated with promoter hypermethylation and unfavorable prognosis.
    • High FGL2 expression was linked to improved patient outcomes and a better response to anti-PD-L1 immunotherapy.
    • FGL2 expression correlated with various immunological features within the BLCA tumor microenvironment.

    Conclusions:

    • FGL2 is downregulated in BLCA, negatively correlated with DNA methylation, and serves as an independent prognostic risk factor.
    • FGL2 is a potential predictive biomarker for immunotherapy response in bladder cancer patients.